NCT04886622View on ClinicalTrials.gov

A Study of DT2216 in Relapsed/Refractory Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 25, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Solid TumorHematologic Malignancy
Interventions
DRUG

DT2216

DT2216 will be administered by intravenous infusion

Trial Locations (3)

60611

Northwestern University, Chicago

75230

Mary Crowley Cancer Research, Dallas

78222

Mays Cancer Center, San Antonio

Sponsors
All Listed Sponsors
lead

Dialectic Therapeutics, Inc

INDUSTRY

NCT04886622 - A Study of DT2216 in Relapsed/Refractory Malignancies | Biotech Hunter | Biotech Hunter